Loading
A phase 2 trial of Oregovomab, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05605535 by CanariaBio Inc., with 88 participants planned, started 2023-02-07 and due to reach its primary completion in 2026-10-15. Interventions recorded: Oregovomab, Paclitaxel, Carboplatin, Placebo. Conditions listed: Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.
Shares CanariaBio, Oregovomab, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares CanariaBio, Oregovomab, Ovarian cancer.